Collectively, Atsttrin could be considered a therapeutic agent in the therapy of Parkinson’s disease via targeting TNFα and in this case could be a future novel drug candidate for the treatment of neurodegenerative diseases. This evidence concerns the gene TNF and neurodegenerative disease.